In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept in playing catch up with ...

Biogen’s late-stage lupus candidates may not have crossed the FDA finish line yet, but the company has already hit the ground ...

For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' ...

The appointments are “a direct response to where our clients need us most,” Michael Maslansky, CEO of m+p, said in a ...

Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across ...

As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping ...

The FDA approval of Bixlenvo tees up a new HIV treatment option for virologically suppressed adults, including those on ...

With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. | Roche is taking a ...

Bristol Myers Squibb, by way of its RayzeBio unit, has taken a big step in furthering its commitment to radiopharmaceuticals, ...

By Alicia Cowley, MD, MBA, Medical Director, Phreesia Network Solutions | Endemic media and broad reach each do half the job.

Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched a phase 3 win in eosinophilic esophagitis (EoE) as ...

Frontier Large Language Models have improved. More data became accessible. Neither solved the hardest questions. Here's what ...